Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Jul;34(7):1459–1461. doi: 10.1128/aac.34.7.1459

Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

T G Cantú 1, J D Dick 1, D E Elliott 1, R L Humphrey 1, D M Kornhauser 1
PMCID: PMC176003  PMID: 2386376

Abstract

Atypical vancomycin pharmacokinetics were observed in an immunoglobulin A myeloma patient. Drug concentrations in serum were extremely elevated, the elimination half-life was prolonged despite normal renal function, and the vancomycin therapy was ineffective. Extensive binding of vancomycin, presumably by high concentrations of an aberrant immunoglobulin A protein, may have accounted for these observations.

Full text

PDF
1459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman B. H., Taylor E. H., Olsen K. M., Abdel-Malak W., Pappas A. A. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm. 1988 Apr;22(4):300–303. doi: 10.1177/106002808802200404. [DOI] [PubMed] [Google Scholar]
  2. Assandri A., Bernareggi A. Binding of teicoplanin to human serum albumin. Eur J Clin Pharmacol. 1987;33(2):191–195. doi: 10.1007/BF00544566. [DOI] [PubMed] [Google Scholar]
  3. Calain P., Krause K. H., Vaudaux P., Auckenthaler R., Lew D., Waldvogel F., Hirschel B. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis. 1987 Feb;155(2):187–191. doi: 10.1093/infdis/155.2.187. [DOI] [PubMed] [Google Scholar]
  4. Cutler N. R., Narang P. K., Lesko L. J., Ninos M., Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984 Dec;36(6):803–810. doi: 10.1038/clpt.1984.260. [DOI] [PubMed] [Google Scholar]
  5. Filburn B. H., Shull V. H., Tempera Y. M., Dick J. D. Evaluation of an automated fluorescence polarization immunoassay for vancomycin. Antimicrob Agents Chemother. 1983 Aug;24(2):216–220. doi: 10.1128/aac.24.2.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Galanakis N., Giamarellou H., Vlachogiannis N., Dendrinos C., Daikos G. K. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections. Eur J Clin Microbiol Infect Dis. 1988 Apr;7(2):130–134. doi: 10.1007/BF01963065. [DOI] [PubMed] [Google Scholar]
  7. Hoffstedt B., Walder M. Influence of serum protein binding and mode of administration on penetration of five cephalosporins into subcutaneous tissue fluid in humans. Antimicrob Agents Chemother. 1981 Dec;20(6):783–786. doi: 10.1128/aac.20.6.783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Krogstad D. J., Moellering R. C., Jr, Greenblatt D. J. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980 Apr;20(4 Pt 1):197–201. doi: 10.1002/j.1552-4604.1980.tb01696.x. [DOI] [PubMed] [Google Scholar]
  9. Lindholm D. D., Murray J. S. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med. 1966 May 12;274(19):1047–1051. doi: 10.1056/NEJM196605122741902. [DOI] [PubMed] [Google Scholar]
  10. Matzke G. R., McGory R. W., Halstenson C. E., Keane W. F. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984 Apr;25(4):433–437. doi: 10.1128/aac.25.4.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Matzke G. R., Zhanel G. G., Guay D. R. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986 Jul-Aug;11(4):257–282. doi: 10.2165/00003088-198611040-00001. [DOI] [PubMed] [Google Scholar]
  12. Merrikin D. J., Briant J., Rolinson G. N. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother. 1983 Mar;11(3):233–238. doi: 10.1093/jac/11.3.233. [DOI] [PubMed] [Google Scholar]
  13. Moellering R. C., Jr, Krogstad D. J., Greenblatt D. J. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med. 1981 Mar;94(3):343–346. doi: 10.7326/0003-4819-94-3-343. [DOI] [PubMed] [Google Scholar]
  14. Nielsen H. E., Hansen H. E., Korsager B., Skov P. E. Renal excretion of vancomycinin in kidney disease. Acta Med Scand. 1975 Apr;197(4):261–264. doi: 10.1111/j.0954-6820.1975.tb04914.x. [DOI] [PubMed] [Google Scholar]
  15. Rodvold K. A., Blum R. A., Fischer J. H., Zokufa H. Z., Rotschafer J. C., Crossley K. B., Riff L. J. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988 Jun;32(6):848–852. doi: 10.1128/aac.32.6.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rotschafer J. C., Crossley K., Zaske D. E., Mead K., Sawchuk R. J., Solem L. D. Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations. Antimicrob Agents Chemother. 1982 Sep;22(3):391–394. doi: 10.1128/aac.22.3.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Tompsett R., Shultz S., McDermott W. The Relation of Protein Binding to the Pharmacology and Antibacterial Activity of Penicillins X, G, Dihydro F, and K. J Bacteriol. 1947 May;53(5):581–595. doi: 10.1128/jb.53.5.581-595.1947. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wise R., Gillett A. P., Cadge B., Durham S. R., Baker S. The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis. 1980 Jul;142(1):77–82. doi: 10.1093/infdis/142.1.77. [DOI] [PubMed] [Google Scholar]
  19. Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet. 1986 Nov-Dec;11(6):470–482. doi: 10.2165/00003088-198611060-00004. [DOI] [PubMed] [Google Scholar]
  20. Wise R. The relevance of pharmacokinetics to in-vitro models: protein binding--does it matter? J Antimicrob Chemother. 1985 Jan;15 (Suppl A):77–83. doi: 10.1093/jac/15.suppl_a.77. [DOI] [PubMed] [Google Scholar]
  21. Wittendorf R. W., Swagzdis J. E., Gifford R., Mico B. A. Protein binding of glycopeptide antibiotics with diverse physical-chemical properties in mouse, rat, and human serum. J Pharmacokinet Biopharm. 1987 Feb;15(1):5–13. doi: 10.1007/BF01062935. [DOI] [PubMed] [Google Scholar]
  22. Zokufa H. Z., Solem L. D., Rodvold K. A., Crossley K. B., Fischer J. H., Rotschafer J. C. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil. 1989 Sep-Oct;10(5):425–428. doi: 10.1097/00004630-198909000-00010. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES